← boardnext 2028-05next 2029-01
IMNM
Immunome, Inc.distress 3/10 · well-funded / low risk$22.07-4%today-18% from 52w high
Oncology 1
Lead: Healthy Volunteer · target Gamma-secretase
Revenue
pre-revenue
Liquidity
$583M
Runway
3.0 yrs
Shares 1y
+30%
Price & events
-14.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.5%
1D
-0.6%
1W
+14.2%
1M
-4.0%
3M
-14.7%
6M
+92.8%
1Y
+48.9%
2Y
+29.7%
5Y
+126.4%
All
Overview
- Market Cap
- $2.50B
- Volume
- 61.65K
- 52 Week Range
- $8.40 – $26.97
- Total Shares
- 113.25M
- Float Shares
- 108.31M
- Short %
- 17.94%
- % Held by Insiders
- 6.30%
- % Held by Institutions
- 108.43%
- RVOL
- 0.04x
- Beta
- 2.07
Pipeline stages · 4 programs
IM-1021
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IM-1617
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Varegacestat Reference Formulation, Varegacestat Test FormulationGamma-secretase
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AL102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-05 Estimated 50% readout ~2028-05-31 | Phase 1 | IM-1021 | Solid Malignancies, Hematologic Malignancies | — | recruiting |
| 2029-01 Estimated 50% readout ~2029-01-31 | Phase 1 | IM-1617 | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | — | recruiting |
| 2026-06 | Phase 1 | Varegacestat Reference Formulation, Varegacestat Test Formulation | Healthy | 20 | recruiting |
| 2025-12-03 | Phase 2/3 | AL102 | Desmoid, Desmoid Tumor | 198 | active not recruiting |
| 2025-11-05 | Phase 1 | varegacestat | Healthy Volunteer, Hepatic Impairment (HI) | 35 | completed |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-04-08 | Phase 1 | varegacestat, Moxifloxacin 400 mg | Healthy Volunteer | 32 | completed |
| 2025-03-11 | Phase 1 | varegacestat | Healthy Volunteer | 6 | completed |
Catalyst news & presentations · 6
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026regulatory submissionFiled (NDA/BLA)varegacestat · Plan to submit NDA to FDASEC 8-K
- second half of 2025readoutPhase 3varegacestat · Phase 3 RINGSIDE Part B topline dataSEC 8-K
- second half of 2025trial initiationsecondaryPhase 1IM-3050 · initiate Phase 1 clinical trialSEC 8-K
- first quarter of 2025regulatory submissionFiled (NDA/BLA)IM-3050 · IND submission expectedSEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 1IM-1021 · Phase 1 trial enrollment expected to commenceSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $36 (+62% upside) · 13 analysts
- 2026-07-21WedbushOutperform
- 2026-06-12WedbushOutperform
- 2026-05-28BarclaysOverweight
- 2026-05-28Truist SecuritiesBuy
- 2026-05-15Leerink PartnersOutperform
- 2026-05-13HC Wainwright & Co.Buy
Competitors — Gamma-secretase
- none identified
Recent news
- 2026-07-21IMNM Reiterates by Wedbush -- Price Target Maintained at $31 - GuruFocus
- 2026-07-21IMNM Reiterates by Wedbush -- Price Target Maintained at $31 - GuruFocus
- 2026-07-20Immunome doses first patient in IM-3050 trial - grafa.com
- 2026-07-20Immunome doses first patient in IM-3050 cancer therapy trial By Investing.com - Investing.com South Africa
- 2026-07-20Immunome doses first patient in IM-3050 cancer therapy trial By Investing.com - Investing.com Nigeria
- 2026-07-20Immunome (IMNM) Begins Phase 1 Trial for IM-3050 in Advanced Sol - GuruFocus
- 2026-07-20Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Business Wire
- 2026-07-19Price-Driven Insight from (IMNM) for Rule-Based Strategy - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.